Table 2.

Antihypertensive medication nonadherence percentages, half-lives, and prescription frequencies.

Drug∗	Class	Number of patients prescribed	Nonadherence (%)	t1/2 (h)	References for t1/2
Bendroflumethiazide	Thiazide	22	45.5	3–8.5	[42]
Ramipril	ACEi	18	44.4	13–17	[43]
Doxazosin	α-blocker	74	41.9	22	[44]
Atenolol	β-blocker	10	40.0	6–9	[45]
Olmesartan	ARB	10	40.0	10–15	[46]
Spironolactone	PSD	66	37.9	2.8–11.2	[47]
Lisinopril	ACEi	28	35.7	12.6	[48]
Indapamide‡	Thiazide	41	34.1	14–18	[49]
Losartan	ARB	36	30.6	6–9	[50]
Amlodipine	CCB	76	30.3	35–50	[51]
Candesartan	ARB	50	24.0	9	[52]
Bisoprolol	β-blocker	67	20.9	10–12	[53]
Amiloride	PSD	16	18.8	6	[54]
Nifedipine†	CCB	27	18.5	6–11	[55]
Felodipine	CCB	12	16.7	25	[56]
Lercanidipine	CCB	18	16.7	8–10	[57]
Chlortalidone‡	Thiazide	17	11.8	40–50	[58]

ACEi indicates angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker, BB = beta-blocker, CCB = calcium channel blocker, PSD = potassium sparing diuretic.

^∗Drugs were only included in the analysis when prescribed for >10 patients.

^†None of the patients were on short acting nifedipine.

^‡Chlortalidone and indapamide are both thiazide-like diuretics.